ACC GUIDELINES Bundle

UA/NSTEMI (ACCF Bundle)

ACC GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/222897

Contents of this Issue

Navigation

Page 48 of 49

Size of Treatment Effect CLASS IIb CLASS III No Benefit or Benefit ≥ Risk CLASS III Harm Additional studies with broad Procedure/ objectives needed; additional registry Test data would be helpful Not Helpful COR III: Procedure/Treatment No benefit MAY BE CONSIDERED Excess Cost COR III: w/o Benefit Harm or Harmful ▪Recommendation's usefulness/ efficacy less well established ▪Greater conflicting evidence from multiple randomized trials or metaanalyses ▪Recommendation's usefulness/ efficacy less well established ▪Greater conflicting evidence from single randomized trial or nonrandomized studies Treatment No Proven Benefit Harmful to Patients ▪Recommendation that procedure or treatment is not useful/effective and may be harmful ▪Sufficient evidence from multiple randomized trials of meta-analyses ▪Recommendation that procedure or treatment is not useful/effective and may be harmful ▪Evidence from single randomized trial or nonrandomized studies ▪Recommendation's usefulness/ efficacy less well established ▪Recommendation that procedure or treatment is not useful/effective and may be ▪Only diverging expert opinion, case harmful studies, or standard of care ▪Only expert opinion, case studies, or standard of care may/might be considered may/might be reasonable usefulness/effectiveness is unknown/ unclear/uncertain or not well established COR III: No Benefit is not recommended is not indicated should not be performed/ administered/other is not useful/ beneficial/effective COR III: Harm potentially harmful causes harm associated with excess morbidity/mortality should not be performed/ administered/other b Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior MI, history of HF, and prior ASA use. c For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated. 47

Articles in this issue

Archives of this issue

view archives of ACC GUIDELINES Bundle - UA/NSTEMI (ACCF Bundle)